Clovis and BMS combine cancer drugs in late-stage trials

07:09 EDT 1 Aug 2017 | pharmaphorum

Clovis Oncology is looking to make the most of its only approved cancer drug, Rubraca, by combining it in two late stage trials with Bristol-Myers Squibb’s blockbuster immunotherapy, Opdivo. Approved by the FDA late last year in ovarian cancer, ...

Original Article: Clovis and BMS combine cancer drugs in late-stage trials


More From BioPortfolio on "Clovis and BMS combine cancer drugs in late-stage trials"

Quick Search

Relevant Topics

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...